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Results of adjuvant dose intensification studies in patients with localised breast cancer have raised questions regarding the clinical
usefulness of this treatment strategy. Here, we develop and fit a natural history model for the time to clinical tumour recurrence as a
function of the number of involved lymph nodes, and derive plausible predictions of the effects of dose intensification under various
conditions. The time to tumour recurrence is assumed to depend on the residual postoperative micrometastatic burden of tumour,
the fractional reduction of residual tumour burden (RTB) by treatment, and the rate of regrowth of the RTB to a clinically detectable
size. It is assumed that a proportion of micrometastatic tumours are unresponsive to adjuvant chemotherapy even at maximal dose
intensity. Data fitted included the San Antonio Cancer Institute (SACI) database of untreated patients, and CALGB #9082, a study
comparing a highly intensive and moderately intensity adjuvant regimen in patients with 10þ positive axillary nodes. The proportion
of tumours unresponsive to maximally intensive adjuvant treatment is estimated to be 48% (29–67%). The estimated log kill for
intermediate-dose therapy from CALGB #9082 was 6.5 logs, compared with 9 logs or greater for high-dose therapy. The model is
consistent with a modest but nonnegligible advantage of dose intensification compared with standard therapies in patients with
sensitive tumours who have 10þ positive axillary nodes, and suggests that much of this clinical benefit could be achieved using
intermediate levels of treatment intensification. The model further suggests that, in patients with fewer than 10 involved axillary
nodes, any advantage of treatment intensification over standard therapy would be much reduced, because in patients with smaller
tumour burdens of sensitive tumour, a larger proportion of cures achievable with intensified therapy could be achieved as well with
standard therapy.
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Several large prospective randomised clinical trials have suggested
a modest increase in relapse-free survival (RFS) with chemother-
apeutic treatment intensification in patients with 10 or more
positive axillary nodes, while others have not (Roche et al, 2003;
Rodenhuis et al, 2003; Tallman et al, 2003; Zander et al, 2004).
Thus, the clinical circumstances under which patients might
benefit from this effect remain to be identified. To guide design
choices for future clinical trials of dose intensification in the
adjuvant therapy of human breast cancer, we have developed a
mathematical model to extract information regarding the natural
history of breast cancers and their sensitivity to chemotherapy
from clinical RFS curves.
The time to postoperative recurrence of a tumour in an
untreated patient is determined by: (1) the size of the subclinical
residual tumour burden (RTB) following surgery and (2)
the growth curve trajectory for the residual tumour in that patient
(see Figure 1). Therefore, from the RFS curve for a cohort of
untreated patients, it might be possible to estimate the distribution
of RTB and the distribution of growth trajectories. In patients
who receive systemic adjuvant treatment, the RTB after
treatment depends, at minimum, on three things: the RTB after
surgery but before treatment, the dose and schedule of the
treatment, and the sensitivity of the cancer cells to the treatment.
Therefore, from the RFS curve for treated patients, it might be
possible to estimate the response of tumour to adjuvant therapy.
(Here the RFS estimate treats deaths without prior recurrence as
censored, because the model is intended to infer the relationship
between underlying tumour biology and clinical tumour beha-
viour.)
Many elements of earlier models have been incorporated
into the model proposed in this paper. The model assumes
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sGompertzian growth (Laird, 1969; Norton, 1988), and simulta-
neously fits the parameters of the RTB distribution and the
micrometastatic tumour growth rate distribution to the RFS curve
(Gregory et al, 1991). To model the effects of systemic therapy, we
have adopted the log-kill hypothesis (Skipper et al, 1964, 1965),
with the additional assumption that there may be a distinct subset
of patients with tumours that are absolutely resistant to even the
most intensive regimens that can be administered clinically. This
assumption provides the simplest model allowing for both highly
responsive and highly unresponsive patients.
The analysis leads to quantitative estimates of the RTB
distribution, the subclinical tumour growth rate distribution, the
proportion of patients with resistant tumours, and the log kill as a
function of treatment intensity. The impact of simplifying
assumptions and other potential sources of error on the estimates
is substantial (see Appendix A1), but the broad insights are
reasonably robust. Therefore, the goal of this investigation is
limited to providing plausible qualitative explanations for the
clinical trial results that can stimulate hypotheses to guide
the performance of overviews and the design of future clinical
trials.
MATERIALS AND METHODS
Model
The time to tumour recurrence is treated as a deterministic
function of the residual postoperative micrometastatic tumour
burden and the growth path of micrometastatic disease, each of
which are random and independent (see Figure 1). The convolu-
tion of these two distributions generates RFS curves that are fitted
to clinical data. Mathematical details and rationales for key
modelling decisions are provided briefly in Appendix A1, and
extensively in a technical supplement available at the website
www.oncotcap.pitt.edu/docs/recurrence-overview.
The fitting of RFS curves, even in the absence of systemic
treatment and even with large sample sizes, poses serious
identifiability problems; that is, even a relatively simple model
requires more parameters than can be simultaneously and
accurately estimated. To reduce the number of parameters and
obtain reasonably stable estimates, strong assumptions have been
made. The two random quantities, the RTB and the growth rate,
are assumed independent of each other. The growth of micro-
metastases is assumed to follow the Gompertz growth model.
Certain parameters are assigned fixed values, including the
Gompertz plateau (10
13 cells), the deceleration rate (1), and a
minimum value for the time from one cell to recurrence (6
months). The two parameters governing the RTB are assumed to
change linearly with increasing numbers of involved axillary nodes
(as ordered categories).
The cytoreductive effects of a chemotherapeutic drug regimen
are modelled by shifting the tumour burden distribution down-
ward by a fixed proportion, in accordance with the log-kill
hypothesis. Intratumour heterogeneity is not modelled. Instead,
the ‘log kill’ represents a net fractional reduction in tumour cell
tumour burden across tumour cell subpopulations and over the
entire course of adjuvant treatment. Effects of systemic therapy on
growth rates of tumour cells are assumed to be transient (lasting
days to weeks) and are not taken into account. The magnitude of
the log-kill shift is assumed to vary with treatment intensity, but
not necessarily in proportion to dose. Intertumour heterogeneity
in responsiveness to chemotherapy is represented as a two-point
distribution, with one point anchored at log kill¼zero. Thus, it is
assumed that a proportion of tumours is unresponsive even to
maximally intensive therapy. This proportion of absolutely
resistant tumours is treated as another model parameter to be
fitted. The apparent conflict between this assumption and
observations of partial or complete responses is discussed in
Appendix A1.
Data sets
Data from the San Antonio Cancer Institute (SACI) on 3217
postoperative breast cancer patients with stage I–III disease
who received no systemic chemotherapy or hormonal therapy
postoperatively were kindly provided by Dr Gary Clark. These
data were used to estimate the distribution of RTBs of tumour
and the distribution of growth rate parameters in untreated
patients. Deaths prior to recurrence were treated as censored.
To reduce computational burden from numerical integration,
the fitting was applied to a subsample consisting of 15.4%
(400/2595) randomly sampled from the 81% who were node-
negative, together with all (622) node-positive patients. The
results were compared to the omitted patients and to a similar
data set, NSABP B04, obtained through the generosity of Dr John
Bryant.
In 1999, CALGB #9082, an intergroup randomised study of
patients with 10 or more positive nodes treated with either a highly
dose-intensive or intermediately intensive chemotherapeutic regi-
men was presented and published in abstract form (Peters et al,
0
3
6
9
12
0 24 48 72 96 120 144 168
Time (months)
Surgery
Times to tumour recurrence
Large residual
body burden
Small residual
body burden
L
o
g
 
c
e
l
l
 
n
u
m
b
e
r
Figure 1 Schematic representation of the factors that affect the
postoperative time delay to clinical detection of micrometastatic disease,
and their relation to RFS curves in patients with stage I–III breast cancer.
The log of tumour cell number is plotted as a function of time. Tumours are
assumed to undergo growth retardation as they enlarge. The threshold for
clinical detection of disease is assumed to be B1 10
9 cells (approxi-
mately 1g of tumour, which may occupy 0.5–10cm
3, depending on
stromal components and oedema). Large postoperative burdens of residual
micrometastatic disease (say 410
7 cells) are likely to recur early (say,
within 1–2 years). Small micrometastatic tumour burdens (o1 10
3 cells)
are likely to cross the threshold of clinical detection later than large
micrometastatic tumour burdens. Since the growth rate characteristics of
micrometastatic tumours of comparable size may vary from patient to
patient, it is to be expected that there will be overlap in times to
recurrence among patients with small and large micrometastatic tumour
burdens, particularly among patients with intermediate micrometastatic
tumour burdens and intermediate subclinical growth rates. If micrometas-
tases can lie dormant for long periods and then commence to grow rapidly,
their behaviour would be indistinguishable in the present model from
continuously slowly growing micrometastases that recur clinically at
comparable times.
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s1999). At that time, the median time on study was roughly 3 years.
The findings after 5 years of follow-up were updated at a
National of Institutes of Health-sponsored consensus conference
in November of 2000, including ‘RFS’ data in which deaths
without recurrence were treated as censored (Peters et al, 2000).
Both the high- and intermediate–dose (ID) RFS curves exhibited
reverse sigmoid shapes, decreasing slowly during the first 6–9
months, more rapidly over the next 4–5 years, and more
slowly again thereafter. The high- and ID RFS curves were
nearly superimposable during the first 6 months of follow-up,
and then diverged. By the second year of follow-up, the difference
between the two curves appeared to stabilise, and was main-
tained between 7 and 12% thereafter. This is discussed further
below.
After 5 years of follow–up, the fraction of high-dose patients
free of recurrence was approximately 0.65, and that of ID patients
was approximately 0.57. Owing to 7% of the early treatment-
related early deaths on the high-dose arm, comparability of the
two RFS curves is of course not assured. In principle, it is possible
that in the absence of fatal complications, these patients
would have all relapsed in the first 5 years. This would yield a
high-dose arm 5-year RFS rate of 60% instead of 65%, eliminating
most of the observed difference in the arms. If instead, those
susceptible to fatalities would have been at higher risk for early
recurrence with an odds ratio of 2, then the combined high-dose
RFS rate at 5 years would be 63.5%, little different from the
observed 65%. Therefore, we are fairly comfortable in tentatively
neglecting this issue.
These data points from the published abstract were used to
estimate the resistant fraction, as detailed below. Recently
published high-dose RFS curves are similar to those of CALGB
#9082. The fractions of high-dose patients free of recurrence at 5
years are in the range of 0.58–0.62 (Roche et al, 2003; Rodenhuis
et al, 2003; Tallman et al, 2003).
Strategy for model fitting
The initial step was to jointly estimate the shared growth
distribution and the individual residual tumour distributions
for four axillary nodal status groups, defined, respectively, as
patients with zero, 1–3, 4–9, or 10þ positive axillary nodes,
using the SACI database. The per cent of patients with absolutely
resistant disease was estimated by fitting the 5-year RFS rate
from the high-dose arm of the CALGB #9082, assuming a log kill of
9 for the sensitive patients to represent the maximal log kill. The
log kill for the ID arm was then estimated assuming the same fixed
per cent of absolutely resistant tumours. A representative log kill
for standard dose was taken to be roughly the median of fitted
values from a set of 5-year RFS rates from published studies. The
identity of constituent chemotherapy agents was ignored for this
purpose. Finally, implications were derived assuming that the
estimated proportion of patients with resistant tumours is
independent of the degree of lymph node involvement. Where
possible, sensitivity analysis relative to the assumptions was
performed.
Parameter estimation
Estimation was based on the method of maximum likelihood.
Likelihoods were computed by numerical integration, speci-
fically the adaptive 15-point Gauss–Kronrod quadrature as
implemented in Splus
s. Maxima were calculated using the
Newton–Gauss–Seidel method. No evidence of multimodality
was found. Confidence intervals for parameters were based on the
Hessian matrices, and the delta method was used to obtain
variance estimates for the plateau as a function of the para-
meters.
RESULTS
RTB in relation to the number of involved axillary nodes
Model-predicted RFS distributions for node-negative and node-
positive patients are compared to the estimated SACI RFS
distributions (Figure 2). The node-positive model-based curve is
a mixture of curves for the three node-positive subgroups,
weighted by the SACI node distribution. The estimated proportion
of patients rendered relapse free by surgery (RFS curve at T¼N)
is 65% (56–75%) for node-negative and 32% (29–35%) for node-
positive patients (95% confidence intervals within parentheses).
The RFS estimates for each of the four node groups are shown in
Figure 3. The family of fitted curves is consistent with a direct
relationship between RTB and the number of involved axillary
nodes. The estimated proportions of patients rendered relapse free
by surgery alone were 65, 41, 21, and 9% for patients with no
axillary node involvement, 1–3 positive nodes, 4–9 positive nodes,
and 10 or more positive nodes, respectively. The goodness of fit for
10þ positive nodes is adequate for the purpose (P¼0.17 using
log-rank test vs simulated data with N¼10000).
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Figure 2 The model was applied to RFS curves from the San Antonio
Database for node-negative and node-positive breast cancer patients. (A)
Actual node-negative and node-positive RFS curves (upper and lower thin-
lined solid curves, respectively) are shown with censored patients marked
by crosses, and are bracketed by dotted curves representing 95%
confidence limits. Corresponding modelled RFS curves are also shown
(thick-lined solid curves), with means at infinite follow-up and 95%
confidence limits for the fitted curves shown to the right of each curve.
(B1) Fitted distribution of residual micrometastatic cell burden for node-
negative patients. Grey zone indicates the portion of the distribution that
represents the proportion of patients with o1 micrometastatic cell (pr),
which was 0.65. (B2) Fitted distribution of residual micrometastatic cell
burden for node-positive patients. The grey zone indicates the portion
(32%) of the distribution corresponding to patients with o1 micrometa-
static cell (pr). (C) Fitted distribution of times to recurrence from a single
cell. It is assumed to be the same for all axillary nodal groups.
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sResponsiveness and resistance to chemotherapy in breast
cancer patients with 10 or more positive axillary nodes
The distributions of RTB and growth rate previously estimated for
untreated patients with 10 or more positive axillary nodes
(Figure 3) were combined with postulated values for the
proportion of patients with absolutely resistant tumours
(Figure 4). From CALGB #9082 (Peters et al, 2000), the RFS
proportion after 5 years was estimated to be 0.65. RFS curves were
calculated as a function of the fraction of absolutely resistant
tumours applied to CALGB #9082. With the assumption that the
log kill in sensitive tumours is maximal (9 or greater), the
maximum-likelihood estimate for the proportion of sensitive
tumours is 48% (95% confidence interval¼29–67% based on
sampling uncertainty in the 5-year point estimate from CALGB
9082).
To estimate the log kill of therapy of ID intensity on sensitive
tumours in the Peters study, this estimate of 48% was used to
derive a family of RFS curves as a function of the log kill (Figure 5).
As the log kill increases, the proportion of patients who remain
relapse free over the long-term increases, but approaches a limit
imposed by the fraction of absolutely resistant tumours. These
curves, particularly those ranging from 3 to 9 logs of cell kill,
exhibit minimal differences during the first year of follow-up, with
larger differences becoming more apparent at later times, in
keeping with clinical findings (Peters et al, 2000; Roche et al, 2003;
Rodenhuis et al, 2003; Tallman et al, 2003). The 5-year RFS
estimate for the Peters ID regimen (Peters et al, 2000) is shown as a
triangle. The maximum-likelihood estimate of the log kill for the
ID regimen is 6.9 logs.
The 5-year RFS points for high-dose regimens from more
recently published studies (Roche et al, 2003; Rodenhuis et al,
2003; Tallman et al, 2003) are and 55%. The log kills for other
high-dose regimens (Roche et al, 2003; Rodenhuis et al, 2003;
Tallman et al, 2003) on sensitive tumours are estimated to range
between 7 and 9 logs, assuming that the sensitive tumour fraction
is again 48%.
Historical and recently published data on the fractions of
patients with 10 or more positive axillary nodes, who survive
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Figure 3 The model was applied to RFS curves from the San Antonio
Database for four different subsets of breast cancer by axillary nodal status:
node negative, 1–3 positive nodes, 4–9 positive nodes, and 10þ positive
nodes. (A) Actual RFS curves (thin-lined solid curves) are shown with
censored patients marked by crosses. Corresponding modelled RFS curves
are also shown (thick-lined solid curves), with means at infinite follow-up
and 95% confidence limits for the fitted curves shown to the right of each
curve. (B1–B4) Fitted distributions of residual micrometastatic cell burden
for subsets of patients modelled in (A). The grey zones indicate the
portions of the distribution that represent patients with o1 micrometa-
static cell (pr). The fitted distribution of times to recurrence from a single
cell is identical to Figure 2C.
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Figure 4 Simulation of RFS in patients with 10 or more positive axillary
nodes following maximally intensive therapy, assuming different propor-
tions of patients with sensitive tumours ranging from 0 to 1.0, in 0.1
increments. Treatment of maximally tolerated intensity is assumed to
produce a 9 log cell kill in sensitive tumours, and is assumed to produce no
effect on resistant tumours. For reference, the value for RFS at 5 years
following treatment of maximal intensity using the Peters regimen (Peters
et al, 2000) is shown (open circle), corresponding to an estimated
probability of a chemosensitive tumour equal to 0.48.
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Figure 5 Simulation of RFS in patients with 10 or more positive axillary
nodes assuming different overall log kills per treatment regimen ranging
from 0 to 1.0, in 0.1 increments. The proportion of patients with sensitive
tumours is assumed to be 0.48 Treatment of maximally tolerated intensity
is assumed to produce a 9 log cell kill in sensitive tumours, and is assumed
to produce no effect on resistant tumours. For reference, the value for RFS
at 5 years following treatment of maximal intensity using the Peters regimen
(5) is shown (open circle). The value for RFS at 5 years for the Peters ID
regimen (5) is shown as an open triangle. A range of estimated values of
RFS at 5 years taken from published studies (see Table 1) is shown as an
bounded vertical line.
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srelapse free 5 years after standard-dose therapy are summarised in
Table 1. In most studies, RFS at 5 years was in the range of 20–
40% (Rodenhuis et al, 2003; Tallman et al, 2003). Figure 5 suggests
that the log kill for standard-dose therapy in sensitive patients with
10 or more positive nodes is in the range of 2–4 logs, with an
upper limit of about 5 logs.
Treatment intensification in patients with fewer than 10
positive axillary nodes
To make predictions for treatment of patients with fewer than 10
positive axillary nodes, we now add the assumption that the
fraction of sensitive micrometastatic tumours changes negligibly
with the degree of nodal involvement. Figure 6 compares model
predictions of the effects of varying the degree of the log kill on
RFS curves, for patient groups defined by the number of positive
axillary nodes. In node-negative patients, the predicted benefit of 2
to 4 logs of cell kill (standard therapy) is modest but real. This
accords with the findings of the 2002 overview update (Early Breast
Cancer Trialists’ Collaborative Group, 2004). The 10-year survival
estimate in node-negative patients was increased by adjuvant
chemotherapy from 71 to 78%. The predicted additional increase
in RFS from increasing the log kill, even to a very high level, is
small. Moving to the other panels, we see that the differences in
RFS between intensive and standard-dose therapy decrease
dramatically as the number of positive nodes decreases.
The four panels of Figure 7 present predicted RFS proportions at
5 years; each panel has identical solid lines, but in each a different
nodal status group is highlighted. The two solid vertical bars in
each panel compare a 7 log-kill to a 9 log-kill range (right bar), and
a 7 log-kill to the 2-to-4-log-kill range (left bar). The heights of
these bars are given in Table 2. Among patients with 10 or more
positive axillary nodes (panel D), the increase from standard
therapy to intermediate therapy (left-hand vertical bar) is
substantial, and the increase from ID to high-dose therapy
(right-hand vertical bar) is smaller but still of some clinical
interest. In contrast, among patients with no positive axillary
nodes (panel A), the smaller log kills associated with standard
therapy would be sufficient to cure the smaller burdens of sensitive
tumours found in most of the node-negative patients who have at
least one remaining viable tumour cell postoperatively (left vertical
bar in Figure 8, panel A). In particular, for patients with four to
nine positive nodes (panel C), the added benefit of high-dose vs ID
Table 1 RFS or event-free survival (*) in patients with 10 or more
positive nodes treated with standard-dose treatment regimens
Regimen
RFS at
5 years
No. of
patients Reference
CMFVP 0.27 56 Jones et al (1987)
CMF 0.23 71 Jones et al (1987)
AC 0.30 34 Jones et al (1987)
FAC 0.52 66 Jones et al (1987)
Adriamycin-containing
standard-dose regimens
0.41 283 Buzdar et al (1992)
CMFVP* 0.30 NA Peters et al (1993)
CMFVP/VATH* 0.32 NA Peters et al (1993)
AC 0.36 106 Fisher et al (1997)
AC, cyclophosphamide
1200mgm
 2
0.34 99 Fisher et al (1999)
FAC 0.52 42 Hortobagyi et al (2000)
CMF or CMF plus tamoxifen* 0.22 141 Schmoor et al (2001)
FEC 0.51 159 Rodenhuis et al (2003)
Tailored FEC 0.58 251 Bergh et al (2000)
CAF 0.52 257 Tallman et al (2003)
FEC 0.40 155 Roche et al (2003)
EC-CMF B0.37 129 Zander et al (2004)
NA¼not applicable.
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Figure 6 Modelled effects of standard therapy (assumed to produce 2–
4 logs of cell kill, shown as shaded region), therapy of intermediate intensity
(producing a 7 log cell kill), and therapy of maximal intensity (producing a 9
log cell kill) in different subsets of patients by nodal status. (A) Node-
negative patients. (B) Patients with 1–3 positive nodes. (C) Patients with
4–9 positive nodes. (D) Patients with 10þ positive nodes.
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demonstrate the principle that the dependence of RFS on the log
kill is steepest in the range of low log kills in patient groups with
the smallest pretreatment RTBs, and steepest in the range of high
log kills in patient groups with the largest pretreatment RTBs.
DISCUSSION
The focus on RFS was driven by the goal of understanding the
dynamics underlying the generation of relapses. This strategy is
subject to the caution that RFS often fails to reflect patient survival.
Arguments for this effect related to Gompertzian growth can be
found (Dang et al, 2003), and early treatment-related mortality
(Peters et al, 2000; Tallman et al, 2003) augments this effect.
Therefore, a model that describes the occurrence of relapses
accurately might well predict patient survival poorly. Nevertheless,
RFS and survival are both affected by residual tumour, by
regrowth, and by treatment effect, so understanding the role of
these three factors better may contribute to understanding better
how to extend survival.
These three factors are likely to be associated with expression of
sets of genes. In explorations of gene expression as predictors of
recurrence, it will be useful to keep in mind that recurrence
depends on RTB, the sensitivity to the administered therapy, and
the regrowth curve. Expression of specific genes may be associated
with one or more of these three factors. If the factors are tightly
correlated (in contradiction to our assumption), then a small set of
genes may be strongly predictive, but if the independence
assumption is closer to the truth, then even a gene group, which
predicts one of the factors with great accuracy may still not predict
recurrence well, because of variance in the other two factors. At the
same time, a fourth source of individual variation, pharmacoki-
netics, may be just as critical. A randomised study compared
marrow-supported high-dose chemotherapy with fluorouracil,
epirubicin, and cyclophosphamide (FEC) ‘tailored’, that is,
individually dose adjusted according to haematologic toxicity
parameters. The RFS was significantly better for the FEC-tailored
arm (Bergh et al, 2000). In contrast, a randomised study
(Rodenhuis et al, 2003), which compared marrow-supported
high-dose chemotherapy to FEC without individual tailoring, did
not show significant differences in RFS at 5 years.
A potential mechanistic explanation for the results of Figures 6
and 7 can be seen in Figure 8. Panel 8A shows model-derived RFS
curves for patients who either were untreated or were treated with
regimens capable of 3, 7, or 9 log kills in sensitive tumours. The
corresponding post-treatment residual body burden distributions
are shown in panels 8B1–8B4. As an estimated B50% of patients
have resistant tumours, successively increasing the log kill leaves a
portion of the RTB distribution unchanged, even with maximal
treatment (8B4). The notches in these distributions reflect the
artificial working assumption of a sharp distinction between
absolutely resistant tumours and sensitive tumours. With increas-
ing log kill, an increasing proportion of modelled patients with
sensitive tumours is rendered relapse free, as indicated by the
progressive shift in the notch point in the distribution to the left.
The regions in panels 8B3 and 8B4 marked by ‘x’ correspond to a
small subset of patients who would experience tumour recurrences
with 9 logs of tumour reduction but not with 7 logs. The time for
the tumours in this subset to grow to a detectable size is
substantial, affecting primarily the later portion of the RFS curve.
Future, recent and forthcoming publications of randomised trials
will provide the ability to check this prediction.
Our simulation studies suggest several conclusions. A sub-
stantial proportion of patients with 10þ axillary nodes, who
receive adjuvant treatment with maximally tolerated systemic
therapy, still develop clinical recurrences. A substantial proportion
of patients may have absolutely resistant tumours. Patients with
sensitive tumours and 10 or more positive nodes may benefit from
treatment intensification, provided that toxicity is manageable, but
much of this clinical benefit might be achieved using ID rather
than HD levels of treatment intensification (Figures 6 and 7).
Finally, the results suggest that patients with fewer than 10
involved axillary nodes, and therefore generally smaller RTBs, who
have sensitive tumours, are more likely to be cured by standard
treatment (Figures 6 and 7), and are, therefore, less likely to benefit
from treatment intensification.
These predictions can be compared with the results of studies
involving adjuvant breast cancer treatment intensification. Several
reviews of these studies have been published (Antman, 2001;
Baynes et al, 2001; Gianni et al, 2001; Rodenhuis et al, 2003). Early
published studies of intensive adjuvant treatment regimens in
postoperative breast cancer patients with 10 or more positive
axillary nodes had small sample sizes or were not randomised.
More recently, two large randomised multiinstitutional adjuvant
treatment intensification trials have been published. For the
French PEGASE 01 trial (Roche et al, 2003), which compares
high-dose therapy with standard therapy in patients with eight or
more positive axillary nodes (4150 patients per treatment arm),
Table 2 Incremental increase in RFS at 5 years, in relation to dose
intensity by axillary nodal status
Node
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1–3
nodes
4–9
nodes 10+ nodes
Intermediate-dose intensity
(7 log kill) vs standard therapy
(2–4 logs)
2–5% 5–10% 8–14% 10–16%
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intermediate-dose therapy (7 log kill)
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Figure 8 (A) A comparison of modelled RFS curves in patients with
10þ positive axillary nodes, who were untreated or were given
treatments that produced 3, 7, or 9 logs of cell kill. For reference, actual
5-year RFSs are shown after treatment with the Peters maximally tolerated
regimen (open circle) and the intermediate regimen (open triangle).
(B1–B4) Modelled distributions of micrometastatic residual cell numbers
after surgery and either no systemic treatment (B1) or systemic therapies
that produce 3 logs (B2), 7 logs (B3), or 9 logs (B4) of cell kill. Shaded areas
in each distribution reflect the probabilities that less than one viable tumour
cell survived after treatment. Oval regions marked by ‘x’ highlight the
differences in the residual body burden distribution as a consequence of a 7
log kill vs a 9 log kill. For discussion, see text.
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smetastasis-free survival was significantly longer for patients who
received high-dose therapy, but overall survival was not. In a
Dutch study (Rodenhuis et al, 2003), comparing the results of
intensive adjuvant therapy with those of standard therapy in high-
risk patients (4440 patients in each treatment arm), only one-
third of the patients had 10 or more positive axillary nodes, while
two-thirds of the patients had 4–9 positive axillary nodes. This
study demonstrated a statistically significant increase in RFS (but
not overall survival) in patients receiving high-dose therapy, only
in those with 10 or more positive axillary nodes. Thus, the RFS
results of the Dutch study are consistent with our conclusions.
Tallman et al (2003) recently reported a study comparing
standard-dose therapy with high-dose therapy in patients with 10
or more positive axillary nodes, with over 250 patients in each arm.
An increase in RFS for high-dose therapy had marginal statistical
significance, sensitive to inclusion of patients with minor protocol
violations.
The study of Peters et al, which has not been published as of this
writing, compares a treatment regimen of maximal intensity with
an aggressive regimen of intermediate treatment intensity in
patients with 10 or more positive nodes, but does not include a
standard therapy arm (Peters et al, 1999, 2000). Each treatment
arm included over 390 patients. The fractions of patients surviving
relapse free after 5 years of follow-up are greater than 0.5 for both
regimens, exceeding the results of any large published studies
involving pure subsets of patients with 10 or more positive axillary
nodes treated with conventional adjuvant treatment regimens.
However, there was substantial treatment-related early mortality in
the high-dose arm.
A small published randomised MD Anderson study involving 78
patients compared high-dose with conventional dose adjuvant
therapy in high-risk patients, and failed to show an advantage for
intensive therapy (Hortobagyi et al, 2000). Most patients had 10 or
more positive nodes at initiation of adjuvant therapy. The study
was designed to detect a true difference of 30% between the
treatments in a 3-year relapse-free interval. From Figures 7 and 8,
such a large difference would not be expected.
A study involving a 50% escalation of doxorubicin dosage in
node-positive patients offered no therapeutic advantage (Budman
et al, 1998). However, a doubling of anthracycline dose has been
reported to produce a statistically significant improvement in RFS
at 5 years in patients with 4 or more positive axillary nodes, but
not in patients with 1–3 positive axillary nodes (The French
Adjuvant Study Group, 2001). This is consistent with the principle
emerging from our studies, which states that benefits of increasing
dose should be greater for patients with greater RTB.
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) examined the role of three levels of intensification of
cyclophosphamide alone in the AC regimen (doxorubicin plus
cyclophosphamide) in operable breast cancer patients with
positive axillary nodes (Fisher et al, 1999). There was no overall
RFS benefit to treatment intensification for patients with 1–3
positive axillary nodes in that study. However, the RFS of patients
with 4–9 positive nodes, who received the most intensive
cyclophosphamide regimen, was significantly better than that of
patients with the lowest cyclophosphamide dose administered
(P¼0.05). In this study, there were over 250 patients with 4–9
positive axillary nodes in each of the treatment arms. In contrast,
there were fewer than 100 patients with 10 or more positive axillary
nodes in each treatment arm. While the RFS curves of patients with
10 or more positive axillary nodes, who received the more
intensive regimens, were higher than for the group that received
the lowest cyclophosphamide dose, the differences did not achieve
statistical significance. This study was not designed to be powered
for subset analysis or interactions with nodal status.
Zander et al (2004) have recently published the initial results of
a German trial in which standard-dose therapy with EC (epirubicin
and cyclophosphamide) and CMF was compared with EC followed
by high-dose therapy with CTM (cyclophosphamide, thiotepa, and
mitoxantrone) in breast cancer patients with 10þ axillary nodes.
The median follow-up time was 3.8 years. The event-free survival
curves exhibited no discernable difference in the first 2 years, but
showed increasing splay at later times. The event-free survival
curve for the high-dose regimen appeared to plateau at 50%, and
the event-free survival curve for the standard-dose regimen
continued to decrease with longer follow-up. However, the
difference was not statistically significant. As noted by the authors,
the power of the study was low due to low patient accrual, and
follow-up duration was too short to draw definitive conclusions.
In relation to the published randomised trials, the models
presented here are broadly consistent, explanatory of some results,
and point towards strategies for investigating dose issues further.
Based on our findings, we would make the following recommenda-
tions for future clinical studies addressing adjuvant dose
intensification in patients with operable breast cancer:
(1) HD protocols should focus on patients with at least 10 positive
nodes. Such patients are not only at the highest risk for
recurrence but also most likely to benefit from the treatment
intensification. Such studies should be powered adequately to
detect differences in RFS, which are in the range of 10% or less
after 5 years of follow-up. Follow-up should be extended well
beyond 5 years, when the clinical outcomes of patients
presumed to have sensitive tumours with small and moderate
RTB’s and/or substantial but noncurative log kills are likely to
have their greatest effects on the RFS curve.
(2) For patients with 4–9 positive axillary nodes, the predicted
magnitude of benefit from ID intensification may be large
enough to warrant study, while the incremental benefit from
high-dose intensification may be too small to justify the excess
risk of toxicity.
(3) Overviews of published randomised studies of dose intensi-
fication should take into account nodal status and/or other
putative correlates of RTB, for example, through subsetting
patients or modelling interaction terms between treatment
and the tumour burden proxy. The time is ripe for such
overviews.
All models use assumptions. Most modelling of clinical data
uses empirical models, with convenience assumptions such as
proportional hazards. The models used here rely on assumptions
with some biological content. Models with biological content can
lead further, but at a risk, because the assumptions will inevitably
be wrong to some degree. A famous aphorism (Box and Draper,
1987) is frequently paraphrased as ‘All models are wrong y some
are useful’. This insight has a new partner (Sterman, 2002): ‘All
decisions are based on models y and all models are wrong.’
Conversely, although knowledge is always incomplete, nonetheless
decisions must be made. Modelling, whether formal and mathe-
matical or informal and purely mental, takes place in the effort to
plan clinical trials or understand their results. Formal modelling
should improve that effort, but cautious consideration of the
assumptions is demanded. It is in this spirit that our modelling
investigations have been conducted.
ACKNOWLEDGEMENTS
We thank Gary Clark for his help in providing data from the San
Antonio Cancer Institute, and John Bryant for provision of data
from the National Surgical Adjuvant Breast and Bowel Program.
The anonymous reviewers contributed a number of excellent
suggestions, for which we are most grateful. This work was
supported in part by Grant R25-CA63548.
Model for RFS curves and treatment intensification
RS Day et al
53
British Journal of Cancer (2005) 92(1), 47–54 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sREFERENCES
Antman KH (2001) A critique of the eleven randomised trials of high-dose
chemotherapy for breast cancer. Eur J Cancer 37: 173–179
Baynes RD, Dansey RD, Klein JL, Hamm C, Campbell M, Abella E, Peters
WP (2001) High-dose chemotherapy and hematopoietic stem cell
transplantation for breast cancer: past or future? Semin Oncol 28:
377–388
Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P,
Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E,
Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C,
Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclopho-
sphamide compared with marrow-supported high-dose chemotherapy
as adjuvant treatment for high-risk breast cancer: a randomised trial.
Scandinavian Breast Group 9401 study. Lancet 356: 1384–1391
Box GP, Draper NR (1987) Empirical Model Building and Response
Surfaces. New York: John Wiley & Sons
Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss
RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E (1998) Dose and
dose intensity as determinants of outcome in the adjuvant treatment of
breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:
1205–1211
Dang C, Gilewski T, Surbone A, Norton L (2003) Cytokinetics. In Cancer
Medicine Kufe DW, Pollock R, Weichselbaum R, Bast R, Holland J, Frei
III E (eds) Chapter 38, 6th edition, online through www.ncbi.nlm.nih.
gov/books. Dekker Inc, Hamilton, Ontario, BC
Early Breast Cancer Trialists’ Collaborative Group (2004) Multi-agent chemo-
therapy for early breast cancer. Cochrane Database Syst Rev CD 000487
Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L,
Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L,
Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic
M, Tan-Chiu E, Tian W, Wolmark N (1999) Further evaluation of
intensified and increased total dose of cyclophosphamide for the
treatment of primary breast cancer: findings from National Surgical
Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17: 3374–3388
Gianni L, Valagussa P, Zambetti M, Moliterni A, Capri G, Bonadonna G
(2001) Adjuvant and neoadjuvant treatment of breast cancer. Semin
Oncol 28: 13–29
Gregory WM, Richards MA, Slevin ML, Souhami RL (1991) A mathematical
model relating response durations to amount of subclinical resistant
disease. Cancer Res 51: 1210–1216
Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ,
Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G,
Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD,
Deisseroth AB, Champlin RE (2000) Randomized trial of high-dose
chemotherapy and blood cell autografts for high-risk primary breast
carcinoma. J Natl Cancer Inst 92: 225–233
Laird AK (1969) Dynamics of growth in tumors and in normal organisms.
Natl Cancer Inst Monogr 30: 15–28
Norton L (1988) A Gompertzian model of human breast cancer growth.
Cancer Res 48: 7067–7071
Peters WP, Rosner G, Hurd D, Norton L, Schilsky R (2000) A prospective,
randomized comparison of two doses of combination alkylating agents
(AA) as consolidation after CAF in high-risk primary breast cancer
involving ten or more axillary lymph nodes (LN): preliminary results of
CALGB 9082/SWOG 9114/NCIC MA-13. In National Institutes of Health
Consensus Development Conference: Adjuvant Therapy for Breast Cancer
pp 101. Bethesda, MD: National Institutes of Health
Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P,
Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L (1999)
A prospective, randomized comparison of two doses of combination
alkyating agents (AA) as consolidation after CAF in high-risk primary
breast cancer involving ten or more axillary lymph nodes (LN):
preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proceed-
ings of the American Society of Clinical Oncology
R o c h eH ,V i e n sP ,B i r o nP ,L o t zJ P ,A s s e l a i nB( 2 0 0 3 )H i g h - d o s ec h e m o t h e r a p y
for breast cancer: the French PEGASE experience. Cancer Control 10: 42–47
Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA,
Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de
Vries EG (2003) High-dose chemotherapy with hematopoietic stem-cell
rescue for high-risk breast cancer. N Engl J Med 349: 7–16
Skipper H, Schabel FM, Wilcox W (1964) Experimental evaluation of potential
anticancer agents. XIII. On the criteria and kinetics associated with
‘curability’ of experimental leukemia. Cancer Chemother Rep 35: 1–111
Skipper H, Schabel FM, Wilcox W (1965) Experimental evaluation of
potential anticancer agents. XIV. Further study of certain basic concepts
underlying chemotherapy of leukemia. Cancer Chemother Rep 45: 5–28
Sterman JD (2002) All models are wrong: reflections on becoming a systems
scientist. System Dyn Rev 18: 501–531
Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP,
Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM (2003)
Conventional adjuvant chemotherapy with or without high-dose
chemotherapy and autologous stem-cell transplantation in high-risk
breast cancer. N Engl J Med 349: 17–26
The French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin
regimen in adjuvant chemotherapy for node-positive breast cancer
patients with poor prognostic factors: 5-year follow-up results of French
Adjuvant Study Group 05 randomized trial. J Clin Oncol 19: 602–611
Zander AR, Kroger N, Schmoor C, Kruger W, Mobus V, Frickhofen N,
Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H,
Possinger K, Trumper L, Kreienberg R, Carstensen M, Schmidt EH,
Janicke F, Schumacher M, Jonat W (2004) High-dose chemotherapy with
autologous hematopoietic stem-cell support compared with standard-
dose chemotherapy in breast cancer patients with 10 or more positive
lymph nodes: first results of a randomized trial. J Clin Oncol 22:
2273–2283
Appendix A1
The assumptions are summarised in Table 3. Detailed discussion
of the models, assumptions, and validations and sensitivity
analyses are presented in an extensive supplement at the website
www.oncotcap.pitt.edu/docs/recurrence-overview. The computer
code can be obtained by e-mail to day@upci.pitt.edu.
Table 3 Modelling assumptions
1. Growth model a. The growth curve model is Gompertzian.
b. The Gompertz plateau is treated as known.
c. The growth parameter t1 has a minimum value (Tg), treated as known.
d. t1– Tg has a lognormal distribution.
2. RTB model a. RTB has a rescaled log b distribution from 10
 6 to 10
9 cells.
b. RTB parameters are linear functions of node group.
c. The cure threshold is treated as known.
d. The recurrence detection threshold is treated as known.
3. Effect of chemotherapy a. Tumours are either fully resistant or sensitive to chemotherapy.
b. The log-kill hypothesis holds among sensitive tumours.
c. Any changes in drug sensitivity over time, such as clonal selection or resistance induction, can be ignored.
d. Any other effects of chemotherapy, such as changes in growth rates of surviving cells, antiangiogenic effects, or suppression of immune
function, can be ignored.
4. Miscellaneous a. The growth curve, residual body burden, and resistant/sensitive patient class are independent.
b. Estimates of RTB and growth curve distributions obtained from an untreated sample are valid for treated patients.
c. Estimates of the proportion of sensitive tumours obtained from the 10+ node sample are valid for other patient groups.
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